Commercial stage specialty pharmaceutical company Fennec Pharmaceuticals (NASDAQ:FENC) (TSX:FRX:CA) said that Adrian Haigh has departed from his position as Fennec’s COO as of June 30, 2024. After nine years as an independent director, in August 2023, Adrian joined the Fennec leadership team as COO. “The company is actively searching for a U.S.-based leader,”Continue Reading
CASI Pharmaceuticals (NASDAQ:CASI) surged in extended trading on Wednesday after the company said it has received a preliminary proposal from CEO Wei-Wu-He to acquire its entire business operations in China. Shares of the China-based biotech were up nearly 80% at $6.41 in trading after the bell. According to the proposal,Continue Reading
Medexus Pharmaceuticals press release (OTCQX:MEDXF): Q4 Adjusted EBITDA of $4.4 million in fiscal Q4 2024, a decrease of $0.4 million, or 8.8%, compared to $4.8 million in fiscal Q4 2023. Adjusted net income of $0.8 million for fiscal Q4, 2024. Revenue of $26M (-9.1% Y/Y) misses by $0.68M. Available liquidity ofContinue Reading
